Drug Profile
Research programme: neurological disorders - Weizmann Institute of Science/ Health Research Institute of Santiago de Compostela
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Weizmann Institute of Science
- Class Enzymes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioblastoma; Stroke
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for preclinical development in Glioblastoma in Israel
- 28 Jan 2020 No recent reports of development identified for preclinical development in Stroke in Israel
- 10 Dec 2015 Weizmann Institute of Science, Health Research Institute of Santiago de Compostela and Sun Pharma agree to co-develop therapies for the treatment of neurological diseases like brain stroke and glioblastom